Scale-up: Getting your ADC Therapeutic to Market Faster hosted by LaunchBio
The global antibody-drug conjugate market size is valued at USD 4.3 billion in 2020 and is expected to see a compound annual growth rate (CAGR) of 23.7% from 2021 to 2028. With such huge market potential, investment dollars are flowing toward ADC start-ups. However, the complex process of scaling up these large molecules for the clinic can present many challenges and requires a significant amount of funding. Join a panel of experts for a discussion on best practices and insights in the process that can help avoid costly pitfalls which can delay your therapeutic going into the clinic and eat up precious investment dollars. Also hear about advances in technologies that can further streamline the process and save a significant amount of funding.
Moderator: Jyothi Swamy, Ph.D., Head of Process & Technology, MilliporeSigma
- Carl Deutsch, Ph.D., Director for ADC Chemistry and Cell Biology, Merck KGaA, Darmstadt, Germany
- Lisa McDermott, Director, Process and Analytical Development, MilliporeSigma